“

First-week fills: 12 of 13 in (NVO limit still resting at 46.08). Best movers are the revenue-generating platforms: MRNA +6, TEM +6, TWST +5, NTRA +4, GH +4. Editing pure-play NTLA flat-to-down with no fresh readout. Anchors VRTX, ALNY, REGN hold the ballast at 0 to 2%. Diversified by necessity: most clinical editing pure-plays (BEAM, CRSP, EDIT, ARWR) reject as invalid here, so XBI carries the small-cap exposure.

”